Dyne Therapeutics to Present at Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Dyne Therapeutics, a leader in muscle disease treatments, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 9:00 a.m. ET. The event can be accessed via a live webcast on the company’s website, with a replay available for 90 days. Dyne is committed to developing innovative therapeutics for genetically driven muscle diseases, utilizing its proprietary FORCE™ platform. Its portfolio includes therapies for myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy.

WALTHAM, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 9:00 a.m. ET.

A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/investors-and-media and a replay will be accessible for 90 days following the presentation.

About Dyne Therapeutics

Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue seen with other approaches. Dyne’s broad portfolio of therapeutic candidates for serious muscle diseases includes programs for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on Twitter, LinkedIn and Facebook.

Contact:

Dyne Therapeutics
Amy Reilly
areilly@dyne-tx.com
857-341-1203

FAQ

When is Dyne Therapeutics participating in the Jefferies Virtual Healthcare Conference?

Dyne Therapeutics will participate in the Jefferies Virtual Healthcare Conference on June 3, 2021, at 9:00 a.m. ET.

How can I watch the Dyne Therapeutics presentation at the conference?

You can watch the Dyne Therapeutics presentation live via webcast on their website in the Investors & Media section.

What therapeutic areas does Dyne Therapeutics focus on?

Dyne Therapeutics focuses on innovative treatments for muscle diseases, specifically targeting myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy.

What is the FORCE™ platform used by Dyne Therapeutics?

The FORCE™ platform is a proprietary technology developed by Dyne Therapeutics to enhance the delivery of oligonucleotide therapeutics to muscle tissue.

Where can I find more information about Dyne Therapeutics?

For more information, visit Dyne Therapeutics’ official website at www.dyne-tx.com.